Details for Patent: 11,613,511
✉ Email this page to a colleague
Which drugs does patent 11,613,511 protect, and when does it expire?
Patent 11,613,511 protects NEXLETOL and NEXLIZET and is included in two NDAs.
This patent has thirty-one patent family members in twelve countries.
Summary for Patent: 11,613,511
| Title: | Methods of making bempedoic acid and compositions of the same |
| Abstract: | The invention provides methods of preparing 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid and methods of making a pharmaceutical material comprising a purified amount of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid. Also provided are compositions and pharmaceutical materials including a purified amount of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid as well as methods of treating various diseases and conditions using the compositions and pharmaceutical materials. |
| Inventor(s): | Richard Copp, Mohamed Abdelnasser, Christopher M. Cimarusti, Jonathan Lane, Michael Barkman, Rasidul Amin, Arthur John Cooper, Damodaragounder Gopal, Philipp Selig |
| Assignee: | Olon Ricerca Bioscience LLC , Esperion Therapeutics Inc |
| Application Number: | US17/742,728 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 11,613,511 |
|
Patent Claim Types: see list of patent claims | Compound; |
Drugs Protected by US Patent 11,613,511
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Esperion Theraps Inc | NEXLETOL | bempedoic acid | TABLET;ORAL | 211616-001 | Feb 21, 2020 | RX | Yes | Yes | 11,613,511 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Esperion Theraps Inc | NEXLIZET | bempedoic acid; ezetimibe | TABLET;ORAL | 211617-001 | Feb 26, 2020 | RX | Yes | Yes | 11,613,511 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,613,511
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2020295503 | ⤷ Start Trial | |||
| Australia | 2020296094 | ⤷ Start Trial | |||
| Australia | 2025203232 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
